Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Anticholinergic and sympathomimetic angle-closure risk
Essential points for quick revision.
2 min synopsisUK scopeSources checked 7 Sept 2026Clinical review pending
!
Painful blurred vision after a medicine exposure
A painful red eye, blurred sight, coloured haloes, headache or vomiting after a relevant medicine can indicate an acute pressure emergency. Do not assume that nausea is the principal illness or that all post-nebuliser pupil changes are benign.
Action: Obtain emergency ophthalmic advice immediately and arrange urgent eye assessment. Record the medicine, route and timing, assess acuity in each eye, and prevent further unintended eye exposure while maintaining necessary treatment for the underlying illness.
Synopsis
Identify avoidable medication exposure in susceptible eyes, recognise acute angle closure, and distinguish pupil-block risk from drug-induced forward displacement of the lens and iris.
The relevant history is the glaucoma mechanism and angle anatomy, not merely a glaucoma label.
Anticholinergic and sympathomimetic pupil dilation can precipitate angle closure in susceptible eyes.
A normal previous pressure measurement does not prove that an angle is safely open.
Key red flags
Ocular pain and haloes occur after nebulised anticholinergic treatment.
Investigation priorities
01
Visual acuity, pupils and slit-lamp assessmentFirst step
Establish functional impact and identify anterior segment signs of an acute attack.
Management branches
Elective prescribingIdentify a relevant contraindication before exposure
An anticholinergic or sympathomimetic medicine is being considered in someone with an eye history.
Clarify the indication and exact medicine, then check the product-specific eye contraindications and cautions.
Review known angle anatomy and seek eye-service advice if a relevant history remains uncertain.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.